 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...121122123124125126127128129130131...143144» |
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change: Neo-Adjuvant Study in Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Oct 8, 2015
P2, N=40, Completed, Sponsor: The Methodist Hospital System
Active, not recruiting --> Completed | N=116 --> 40
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC) (clinicaltrials.gov) - Oct 8, 2015
P2, N=27, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed | N=116 --> 40 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date, Metastases: Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc (clinicaltrials.gov) - Oct 7, 2015
P2, N=24, Terminated, Sponsor: University Hospital of Crete
Active, not recruiting --> Completed N=50 --> 24 | Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Aug 2012; Due to poor Accrual
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, PD(L)-1 Biomarker, IO biomarker, Metastases: Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) (clinicaltrials.gov) - Oct 7, 2015
P2, N=150, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=50 --> 24 | Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Aug 2012; Due to poor Accrual Recruiting --> Active, not recruiting
- |||| Ibrance (palbociclib) / Pfizer
Enrollment open, Metastases: PALATINUS: Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer (clinicaltrials.gov) - Oct 6, 2015
P2, N=120, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas (clinicaltrials.gov) - Oct 3, 2015
P2, N=51, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2015 --> Nov 2016
- || Gilotrif (afatinib) / Boehringer Ingelheim
Trial primary completion date, Combination therapy, Metastases: Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours (clinicaltrials.gov) - Oct 1, 2015
P1, N=58, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Nov 2015 --> Nov 2016 Trial primary completion date: Jul 2015 --> Jan 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 30, 2015
P1, N=43, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2015 --> Jan 2015 Active, not recruiting --> Completed
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Mismatch repair, Microsatellite instability, Metastases: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) (clinicaltrials.gov) - Sep 29, 2015
P3, N=270, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || Biomarker, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 24, 2015
P2, N=610, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Mar 2019 --> Dec 2018
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Sep 24, 2015
P1, N=115, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Mar 2019 --> Dec 2018 Trial primary completion date: Oct 2017 --> Apr 2018
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy: Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0 (clinicaltrials.gov) - Sep 24, 2015
P1, N=21, Active, not recruiting, Sponsor: Lund University Hospital
Trial primary completion date: Oct 2017 --> Apr 2018 Trial primary completion date: Jul 2015 --> Jul 2017
- || Zelboraf (vemurafenib) / Roche
Trial primary completion date: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers (clinicaltrials.gov) - Sep 24, 2015
P2, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jul 2015 --> Jul 2017 Trial primary completion date: Apr 2017 --> Sep 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date: Treatment Regimens for Patients With Resectable Liver Metastases (PANTER Study) (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=16, Terminated, Sponsor: RWTH Aachen University
Trial primary completion date: Apr 2017 --> Sep 2016 N=430 --> 16 | Active, not recruiting --> Terminated | Trial primary completion date: May 2015 --> Sep 2015; Recruitment difficulities
- gedatolisib (PF-05212384) / Celcuity
Enrollment change, Trial primary completion date, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 22, 2015
P2, N=150, Terminated, Sponsor: Pfizer
N=430 --> 16 | Active, not recruiting --> Terminated | Trial primary completion date: May 2015 --> Sep 2015; Recruitment difficulities N=19 --> 150 | Trial primary completion date: Aug 2015 --> Nov 2015
- ||| prexasertib (ACR-368) / Acrivon Therap
New P1 trial, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer (clinicaltrials.gov) - Sep 21, 2015
P1, N=70, Not yet recruiting, Sponsor: Eli Lilly and Company
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (clinicaltrials.gov) - Sep 18, 2015
P2, N=28, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=19 --> 150 | Trial primary completion date: Aug 2015 --> Nov 2015 Trial primary completion date: Dec 2015 --> Dec 2016
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
New P3 trial, Combination therapy, Metastases: KESTREL: Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Sep 16, 2015
P3, N=628, Not yet recruiting, Sponsor: AstraZeneca
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Trial primary completion date: Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT (clinicaltrials.gov) - Sep 15, 2015
P3, N=11, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed | N=40 --> 11 | Trial primary completion date: Aug 2016 --> Sep 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, FDG PET, Metastases: Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer (clinicaltrials.gov) - Sep 14, 2015
P2, N=42, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Completed | N=40 --> 11 | Trial primary completion date: Aug 2016 --> Sep 2015 Active, not recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer (clinicaltrials.gov) - Sep 14, 2015
P2, N=89, Completed, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || merestinib (LY2801653) / Eli Lilly
Trial primary completion date, Metastases: A Study of LY2801653 in Advanced Cancer (clinicaltrials.gov) - Sep 9, 2015
P1, N=190, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Trial primary completion date: Nov 2016 --> Nov 2017
- |||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Combination therapy, Metastases: CHANGE2: Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer (clinicaltrials.gov) - Sep 9, 2015
P3, N=240, Recruiting, Sponsor: Merck KGaA
Trial primary completion date: Nov 2016 --> Nov 2017 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Sep 8, 2015
P2, N=43, Recruiting, Sponsor: Fox Chase Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2015 --> Feb 2016
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date, Metastases: Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study (clinicaltrials.gov) - Sep 4, 2015
P2, N=7, Terminated, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Feb 2015 --> Feb 2016 Trial primary completion date: Sep 2015 --> Jul 2012
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Trial primary completion date, Metastases: SWOG S0819: S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 3, 2015
P3, N=1546, Active, not recruiting, Sponsor: Southwest Oncology Group
Trial primary completion date: Sep 2015 --> Jul 2012 Suspended --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Feb 2017
- ||| lumretuzumab (RG7116) / Roche
Enrollment open, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Sep 3, 2015
P1, N=182, Recruiting, Sponsor: Hoffmann-La Roche
Suspended --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Feb 2017 Active, not recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Metastases: HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver (clinicaltrials.gov) - Sep 3, 2015
P1, N=115, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Aug 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, IO biomarker, Metastases: Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab (clinicaltrials.gov) - Sep 1, 2015
P2, N=55, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Aug 2015 Active, not recruiting --> Completed | N=88 --> 55
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Aug 28, 2015
P2, N=40, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed | N=88 --> 55 Recruiting --> Active, not recruiting
- ||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: AlloStim (clinicaltrials.gov) - Aug 27, 2015
P2/3, N=450, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
Recruiting --> Active, not recruiting Initiation date: Jan 2014 --> Jan 2016 | Trial primary completion date: Jan 2016 --> Jan 2019
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Enrollment closed, Combination therapy, Metastases: Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Aug 27, 2015
P2, N=175, Active, not recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Initiation date: Jan 2014 --> Jan 2016 | Trial primary completion date: Jan 2016 --> Jan 2019 Recruiting --> Active, not recruiting
- |||| Opdivo (nivolumab) / BMS
Trial primary completion date, Metastases: Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) (clinicaltrials.gov) - Aug 21, 2015
P3, N=360, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2016 --> Jul 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN (clinicaltrials.gov) - Aug 21, 2015
P2, N=92, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Oct 2016 --> Jul 2016 Trial primary completion date: Dec 2015 --> Dec 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: A Study in Advanced Solid Tumors (clinicaltrials.gov) - Aug 21, 2015
P2, N=8, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Dec 2015 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> May 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Chemoradiation Treatment for Head and Neck Cancer (clinicaltrials.gov) - Aug 19, 2015
P2, N=60, Active, not recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> May 2015 Trial primary completion date: Jun 2015 --> Dec 2014
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, abituzumab (EMD 525797) / EMD Serono, SFJ Pharma
Trial termination, Trial primary completion date, Combination therapy, Metastases: POSEIDON: EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=229, Terminated, Sponsor: Merck KGaA
Trial primary completion date: Jun 2015 --> Dec 2014 Active, not recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Apr 2015
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 13, 2015
P2, N=38, Completed, Sponsor: New York University School of Medicine
Active, not recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Apr 2015 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: MACRO-2: Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours (clinicaltrials.gov) - Aug 12, 2015
P2, N=194, Completed, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: DEEPER: A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab (clinicaltrials.gov) - Aug 5, 2015
P2, N=360, Not yet recruiting, Sponsor: Japan Clinical Cancer Research Organization
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
New P2 trial, Metastases: FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 25, 2015
P2, N=25, Not yet recruiting, Sponsor: City of Hope Medical Center
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial: NKEXPHNC: Reactivating NK Cells in Treating Refractory Head and Neck Cancer (clinicaltrials.gov) - Jul 23, 2015
P1/2, N=31, Recruiting, Sponsor: National University Hospital, Singapore
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel (clinicaltrials.gov) - Jul 21, 2015
P2, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=260 --> 0
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: CTXMAB+RT: Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jul 17, 2015
P2, N=70, Terminated, Sponsor: Azienda USL 4 Prato
N=260 --> 0 Trial primary completion date: May 2015 --> Dec 2019
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Trial primary completion date, Metastases: Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer (clinicaltrials.gov) - Jul 16, 2015
P2, N=8, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: May 2015 --> Dec 2019 Active, not recruiting --> Completed | N=15 --> 8 | Trial primary completion date: Sep 2015 --> Feb 2015
- ||||| Ibrance (palbociclib) / Pfizer
New P2 trial, Metastases: PALATINUS: Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer (clinicaltrials.gov) - Jul 15, 2015
P2, N=120, Not yet recruiting, Sponsor: Pfizer
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - Jul 15, 2015
P2, N=73, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | N=15 --> 8 | Trial primary completion date: Sep 2015 --> Feb 2015 Completed --> Active, not recruiting
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Trial primary completion date, Metastases: COMETS: Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients (clinicaltrials.gov) - Jul 15, 2015
P3, N=110, Completed, Sponsor: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Completed --> Active, not recruiting Recruiting --> Completed | N=350 --> 110 | Trial primary completion date: Nov 2014 --> Apr 2015
- |||| GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Tumor cell, Metastases: Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Jul 15, 2015
P2, N=60, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed | N=350 --> 110 | Trial primary completion date: Nov 2014 --> Apr 2015 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Surgery, Metastases: Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer (clinicaltrials.gov) - Jul 14, 2015
P=N/A, N=20, Recruiting, Sponsor: Rutgers, The State University of New Jersey
Active, not recruiting --> Completed Not yet recruiting --> Recruiting